Please use this identifier to cite or link to this item:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-37751 | Title: | Neoadjuvante Chemohormontherapie vor Prostatektomie bei Hochrisikoprostatakarzinom : Ist das biochemische Rezidiv ein adäquater Surrogat-Marker für den klinischen Nutzen? |
| Other Titles: | Neoadjuvant chemohormonal therapy prior to prostatectomy in high-risk prostate cancer-is biochemical recurrence an adequate surrogate marker for clinical benefit? |
| Author(s): | Stöckle, Michael |
| Language: | German |
| Year of Publication: | 2020 |
| DDC notations: | 610 Medicine and health |
| Publikation type: | Other |
| DOI of the first publication: | 10.1007/s00120-020-01338-y |
| URL of the first publication: | https://link.springer.com/article/10.1007/s00120-020-01338-y |
| Link to this record: | urn:nbn:de:bsz:291--ds-377518 hdl:20.500.11880/34138 http://dx.doi.org/10.22028/D291-37751 |
| Date of registration: | 27-Oct-2022 |
| Notes: | Der Urologe 59, 1394-1395 (2020) |
| Faculty: | M - Medizinische Fakultät |
| Department: | M - Urologie und Kinderurologie |
| Professorship: | M - Prof. Dr. Michael Stöckle |
| Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
There are no files associated with this item.
Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.